

**IN THE CLAIMS:**

Please cancel claims 1 thru 11 and add new claims 12 thru 25 as follows:

**CLAIMS**

- 12) A method of inducing the death of undesirable cells and/or stimulate an immune response comprising the administration to a patient of a) a substance which promotes the targeting of the PML protein towards the nuclear bodies and /or PML stabilization and b) the PML protein and/or an agent inducing the over expression of the PML protein.
- 13) A method of claim 12 wherein the substance which promotes the targeting of the PML protein towards the nuclear bodies and /or PML stabilization is selected from the group consisting of 1) an arsenic compound; 2) a compound having the same biological properties as arsenic; 3) caspase inhibitors; and 4) caspase substrates.
- 14) A method of claim 13 wherein said arsenic compound is arsenic trioxide.
- 15) A method of claim 13 where said caspase inhibitor is zVAD.
- 16) A method of any one of the proceeding claims wherein said agent inducing the over expression of the BML protein is an ~~interferon~~.
- 17) A method of claim 16 wherein said interferon is selected from the group consisting of  $\alpha$ -interferon,  $\beta$ -interferon and  $\gamma$ -interferon.
- 18) A method of any one of the proceeding claims wherein administration of a and b is simultaneous or sequential.
- 19) A method of inducing the death of undesirable cells and/or stimulate an immune response comprising the administering to a patient a) an arsenic compound, compound having the same biological properties as arsenic, caspase inhibitors or a caspase substrate; and b) an interferon.
- 20) A method of claim 12 wherein the administration of a and b is simultaneous or sequential.
- 21) A method of inducing the death of undesirable cells in vitro comprising bringing undesirable cells in contact with a) an arsenic compound, a compound having the same biological properties as arsenic, a caspase inhibitors or a caspase substrate and b) a substance being associated with the PML protein and/or an agent inducing the expression of the PML protein.
- 22) A pharmaceutical composition comprising:
- at least one caspase inhibitor and/or substrate;
  - at least one arsenic compound or compound having the same biological properties as arsenic;
  - the PML protein;
  - at least one agent inducing the over-expression of the PML protein; and
  - a pharmaceutically acceptable vehicle.